Assembly Biosciences (NASDAQ:ASMB) Issues Quarterly Earnings Results, Beats Expectations By $0.52 EPS

Key Points

• Assembly Biosciences beat quarterly expectations: It reported an adjusted loss of $0.20 per share, $0.52 better than analysts’ forecast, while revenue of $13.37 million exceeded estimates of $8.60 million.
• Shares rose sharply after the results, gaining $2.89 to $29.95 on unusually high trading volume. The company remains unprofitable, with a negative net margin of 8.98%.
• Analysts maintain a “Moderate Buy” consensus, with five Buy, one Hold and one Sell rating and an average price target of $44, while institutional investors own 19.92% of the stock.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.52, FiscalAI reports. The firm had revenue of $13.37 million during the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%.

Assembly Biosciences Price Performance

ASMB traded up $2.89 on Thursday, hitting $29.95. 728,714 shares of the stock were exchanged, compared to its average volume of 148,622. The firm has a market capitalization of $476.00 million, a price-to-earnings ratio of -272.25 and a beta of 1.10. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71. The business has a 50-day moving average of $25.77 and a two-hundred day moving average of $27.33.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ASMB. Weiss Ratings reissued a "sell (d-)" rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Wall Street Zen cut shares of Assembly Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 16th. Guggenheim reiterated a "buy" rating and issued a $43.00 target price on shares of Assembly Biosciences in a research note on Thursday, May 28th. Mizuho set a $45.00 price objective on shares of Assembly Biosciences and gave the company an "outperform" rating in a research report on Monday, June 15th. Finally, HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Assembly Biosciences in a report on Monday, May 4th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $44.00.

Institutional Trading of Assembly Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 3,319 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Assembly Biosciences during the 4th quarter worth $228,000. Virtus Investment Advisers LLC bought a new stake in shares of Assembly Biosciences during the 4th quarter worth $251,000. Engineers Gate Manager LP acquired a new stake in Assembly Biosciences in the fourth quarter valued at about $353,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Assembly Biosciences in the third quarter valued at about $282,000. Institutional investors own 19.92% of the company's stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source